Steve N. Leonard

Assistant Professor
  • Department of Pharmacy Practice
  • School of Pharmacy

Office: 140 The Fenway, R225
Phone: 617-373-5212

Post-Doctoral Research Fellowship, Wayne State University, Detroit, MI
Graduate Certificate in Public Health Practice, Wayne State University, Detroit, MI
Pharmacy Practice Residency, St. Vincent Hospital and Health Services, Indianapolis, IN
Doctor of Pharmacy, Purdue University, West Lafayette, IN
Bachelor of Science in Pharmacy, Purdue University, West Lafayette, IN

Specializations: Infectious Diseases

Investigations surrounding the application of pharmacokinetic and pharmacodynamic principles in the treatment of infections caused by Staphylococcus aureus as well as methods to suppress the emergence of resistance.

Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV.  Comparative In Vitro Activity of Telavancin, Vancomycin, and Linezolid against Heterogeneously Vancomycin Intermediate Staphylococcus aureusInt J Antimicrob Agents2011;37(6):558-561.

Kullar R, Leonard SN, Davis SL, Delgado G, Pogue JM, Wahby KA, Falcione B, Rybak MJ.  Validation of the Effectiveness of a Vancomycin Nomogram in Achieving Target Trough Concentrations of 15-20 mg/L Suggested by the Vancomycin Concensus Guidelines.  Pharamcotherapy 2011;31(5):441-448.

Vidaillac C, Leonard SN, Rybak MJ.  In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.  Int J Antimicrob Agents2010;35(6):527-30.

Rong SL, Leonard SN.  Heterogeneous vancomycin resistance in Staphylococcus aureus: A review of epidemiology, diagnosis, and clinical significance.  Ann Pharmacother 2010;44(5):844-50.

Vidaillac C, Leonard SN, Rybak MJ.  In Vitro Activity of Ceftaroline Against Methicillin-Resistant Staphylococcus aureus and heterogeneous Vancomycin-Intermediate S. aureus Using a Hollow Fiber Model.  Antimicrob Agents Chemother 2009;53(11):4712-7.

Leonard SN, Vidaillac C, Rybak MJ.  Activity of Telavancin Against Staphylococcus aureus of Varying Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations.  Antimicrob Agents Chemother 2009;53(7):2928-2933.

Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ.  In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosaAntimicrob Agents Chemother 2009;53(6):2360-6.

Leonard SN, Rossi KL, Newton KL, Rybak MJ.  Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.  J Antimicrob Chemother 2009;63(3):489-92.

 Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ.  Impact of inoculum and heterogeneous vancomycin intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.  Antimicrob Agents Chemother 2009;53(2):805-7.

Leonard SN, Rybak MJ.  Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.  J Antimicrob Chemother 2009;63(1):155-160.

Leonard SN, Kaatz GW, Rucker LR, Rybak MJ.  Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureusJ Antimicrob Chemother 2008;62(6):1305-10.

Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sadar HS, Jones RN.  Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).   J Clin Microbiol2008;46(9):2950-4.

Rose WE, Leonard SN, Rybak MJ.  Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.  Antimicrob Agents Chemother2008;52(9):3061-7.

Leonard SN, Cheung CM, Rybak MJ.  Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2008;52(8):2974-6.

LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.  Antimicrob Agents Chemother 2008;52(6):2156-62.

Leonard SN, Rybak MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.  Pharmacotherapy 2008;28(4):458-68.

Tsuji BT, Leonard SN, Rhomberg PR, Jones RN, Rybak MJ.  Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum.  Diagn Microbiol Infect Dis 2008;60(4):441-4.

Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MM, Sheth AA, Carpenter CF, Rybak MJ.  Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations.  Antimicrob Agents Chemother 2008;52(3):831-6.